NSAIDs in the treatment and/or prevention of neurological disorders

被引：10
作者：
Parto S. Khansari
Leanne Coyne
机构：
[1] California Northstate College of Pharmacy, Rancho Cordova, CA 95670
来源：
Inflammopharmacology | 2012年 / 20卷 / 3期
关键词：
Alzheimer's disease; Amyotrophic lateral sclerosis; Aspirin; COX-2; Fenamates; Ibuprofen; Inflammation; Neuroprotection; Nimesulide; NSAIDs; Parkinson's disease; Stroke;
D O I：
10.1007/s10787-011-0116-2
中图分类号：
学科分类号：
摘要：
Non-steroidal anti-inflammatory drugs (NSA-IDs) have been used extensively in the treatment of inflammatory disorders and pain. In recent years, emerging data suggest that some NSAIDs possess pharmacological properties, in addition to cyclooxygenase inhibition, which may be beneficial in the treatment of several neurological conditions. For example, fenamate NSAIDs potentiate GABA-A receptor function, indomethacin scavenges nitric oxide free radicals, and acetylsalicylic acid inhibits the translocation of NF-κB, all of which may contribute to their neuroprotective actions in selected experimental models of stroke. The purpose of this review is to explore the diverse pharmacological properties of NSAIDs in relation to their potential value in the treatment of selected neurological diseases. © 2011 CARS.
引用
收藏
页码：159 / 167
页数：8
相关论文
共 90 条
  • [1] Aid S., Bosetti F., Targeting cyclooxygenases-1 and-2 in neuroinflammation: Therapeutic implications, Biochimie, 93, 1, pp. 46-51, (2011)
  • [2] Aktas O., Ullrich O., Infante-Duarte C., Nitsch R., Zipp F., Neuronal damage in brain inflammation, Arch Neurol, 64, 2, pp. 185-189, (2007)
  • [3] Aoki E., Yano R., Yokoyama H., Kato H., Araki T., Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahyropyridine)-induced apop-tosis in nigral neurons of mice, Exp Mol Pathol, 86, 1, pp. 57-64, (2009)
  • [4] Arvin B., Neville L.F., Barone F.C., Feuerstein G.Z., The role of inflammation and cytokines in brain injury, Neurosci Biobehav Rev, 20, 3, pp. 445-452, (1996)
  • [5] Aubin N., Curet O., Deffois A., Carter C., Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice, J Neurochem, 71, 4, pp. 1635-1642, (1998)
  • [6] Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., Buring J., Hennekens C., Kearney P., Meade T., Patrono C., Roncaglioni M.C., Zanchetti A., Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials, Lancet, 373, 9678, pp. 1849-1860, (2009)
  • [7] Barneoud P., Curet O., Beneficial effects of lysine acetylsalic-ylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis, Exp Neurol, 155, 2, pp. 243-251, (1999)
  • [8] Bauman S., Hottecke N., Schubenel R., Baumann K., Schmidt B., NSAID-derived c-secretase modulators. Part III: Membrane anchoring, Bioorg Med Chem Lett, 19, pp. 6986-6990, (2009)
  • [9] Beresford I.J., Parsons A.A., Hunter A.J., Treatments for stroke, Expert Opin Emerg Drugs, 8, 1, pp. 103-122, (2003)
  • [10] Biller J., Antiplatelet therapy in ischemic stroke: Variability in clinical trials and its impact on choosing the appropriate therapy, J Neurol Sci, 284, 1-2, pp. 1-9, (2009)
123456789